Contents 3 min read

Claim and source comparison

St. John’s wort: extracts studied in depression, a placebo-controlled trial and important drug interactions.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Systematic review / meta-analysis

The 2008 Cochrane review included 29 trials and 5489 patients. The studied extracts showed higher response rates than placebo and similar response rates to standard antidepressants.

Placebo comparisons showed marked heterogeneity. Most trials included mild or moderate symptoms. The results cannot be generalized to all extracts or severe depression.

Source 1 · Abstract read

Human randomized controlled trial

The 2002 trial assigned 340 adults with major depression to LI-160 extract, sertraline or placebo. At 8 weeks, neither active treatment differed significantly from placebo on the two primary outcomes.

Because the active comparator did not separate on the primary outcomes, the trial’s ability to detect an effect is uncertain. The result does not automatically apply to other products or treatments.

Source 2 · Abstract read

Official safety summary

NIH NCCIH warns that St. John’s wort can weaken medicines including birth control pills, cyclosporine, digoxin and warfarin, and can cause serious adverse effects with serotonergic medicines.

These are examples of interactions. The list cannot establish safety for medicines it does not mention.

Source 5 · Official summary read

Our evidence and source methodology

St. John's wort: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

⚠ Drug Interaction Warning

St John’s wort can reduce levels of some medicines through effects on drug-metabolizing enzymes and P-glycoprotein; examples include birth control pills, cyclosporine, warfarin, digoxin and some HIV medicines. Combining it with antidepressants also risks serious serotonergic adverse effects. Interactions do not all arise from CYP3A4 alone; starting or stopping use requires discussion with a clinician/pharmacist.

What is St. John's Wort?

St. John's wort (Hypericum perforatum) is a perennial plant belonging to the family of flowering plants. Native to Europe, Asia and North Africa, this plant has been used in traditional folk medicine for centuries for depression, anxiety, wound healing and nerve pain. It is known as St. John's wort or binbirdelik herb in Türkiye.

Extracts vary in hypericin and hyperforin content. A percentage or extract ratio alone does not prove efficacy, safety or equivalence to a trial product; no single percentage is a universal product recommendation.

Mechanism of Effect

St. John's wort: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans. This schematic mechanism illustration does not establish clinical benefit in humans, a receptor reset or a safe dosing schedule.

St John’s wort extracts contain multiple compounds; laboratory effects on neurotransmitter systems do not establish which mechanism produces clinical benefit in humans. An isolated compound does not justify labeling an extract “SSRI-like,” an MAO inhibitor or anxiolytic. Clinical trials assess specific extracts; products are not all equivalent.

Clinical Evidence

The Linde et al. (2008) Cochrane review included 29 trials and 5489 patients. Tested St John’s wort extracts outperformed placebo and had similar outcomes to antidepressants; findings cannot automatically generalize to all products, depression severities or individual treatment.

In a NIH-funded 2002 trial, 340 adults received St John’s wort, sertraline or placebo for 8 weeks. Neither active treatment significantly beat placebo on the two primary outcomes; one trial cannot conclusively settle all treatment of severe depression.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Drug Interactions

St John’s wort may worsen symptoms with bipolar disorder or a history of psychosis. Serotonin-syndrome risk with antidepressants and reduced efficacy of many medicines make self-treatment inappropriate. Pregnancy and breastfeeding safety is not adequately established.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Linde K, et al. (2008). St John's wort for major depression. Cochrane Database of Systematic Reviews. PubMed · PMID 18843608
  2. Hypericum Depression Trial Study Group. (2002). Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA, 287(14), 1807–1814. PubMed · PMID 11939866
  3. Müller WE. (2003). Current St. John's Wort research from mode of action to clinical efficacy. Pharmacological Research, 47(2), 101–109. PubMed · PMID 12543057
  4. Borrelli F, Izzo AA. (2009). Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS Journal, 11(4), 710–727. PubMed · PMID 19859815
  5. National Center for Complementary and Integrative Health. St. John’s Wort: Usefulness and Safety. https://www.nccih.nih.gov/health/st-johns-wort NIH NCCIH

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions